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Patient 1. A 27-year-old man was referred to the Division of Nephrology
at the University of Ban because of recurrent episodes of gross hematuria
concomitant with febrile upper respiratoly tract infections. Several urinal-
yses had revealed persistent microscopic hematuria. On admission, he
presented with an additional episode of gross hematuria accompanied by
sore throat and a flu-like illness. Neither dysuria nor oliguria was present.
He did not complain of any pain or discomfort in his lumbar region.
Physical examination was remarkable only for pharyngitis and tonsillitis
and an oral temperature of 38.7°C. Blood pressure was 110/80mm Hg. No
abnormalities were found in his chest, abdomen, or extremities. Ophthal-
mologic and audiologic examinations were normal. The patient was
treated with an antibiotic (amoxicillin) for 5 days.
Laboratory investigation revealed: glucose, 93 mg/dl; BUN, 21 mg/dl;
serum creatinine, 1.1 mg/dl; creatinine clearance, 91 mI/mm; sodium, 140
mEq/liter; potassium, 4.4 mEq/liter; chloride, 105 mEq/liter; bicarbonate,
26 mEq/liter; total protein, 7.4 g/dl; albumin, 3.5 g/dl; cholesterol, 170
mg/dl; triglycerides, 135 mg/dl; uric acid, 5.6 mgldl; AST, 166 units/liter;
and bilirubin, 0.3 mg/dl. The 24-hour urinary protein excretion was 590
fig. Microscopic examination of the urinary sediment revealed many
erythrocytes and some leukocytes. A urine culture was negative. An
intravenous pyelogram was normal. Immunologic studies revealed normal
serum levels of IgG, 1gM, C4, C3, and factor B; the IgA was 380 mg/dl
(normal value, 50—326 mgjdl).
A percutaneous renal biopsy was performed. Light microscopy revealed
mcsangial proliferation in less than 50% of glomeruli: no glomerular
sclerosis or capsular adhesion was found. No tubulointerstitial changes or
vascular abnormalities were present. Immunofluorescent study showed
only mesangial deposits of IgA and C3.
Three years after the initial presentation, high blood pressure was
detected; enalapril, 10 mg twice daily, was prescribed. Now, 9 years after
the diagnosis of hypertension, he is active and healthy, with normal blood
pressure under pharmacologic control and normal renal function. Protein-
unia ranges between 400 and 700 mg/day. Another episode of gross
hematuria occurred during this period of observation, but renal function
and blood pressure remained normal during the episode.
His father has persistent microscopic hematuria (Fig. 1). His brother
has had frequent episodes of gross hematuria; one year ago, at age 28, a
renal biopsy performed at another hospital disclosed IgA nephropathy.
Light microscopic examination revealed moderate mesangial prolifera-
tion, rare adhesions, and small crescents; focal tubular atrophy and
moderate sclerosis of vessel walls were present. Immunofluorescent
examination showed mesangial deposits of IgA and C3; capillary deposits
were found in some glomeruli. The daughter of the patient's brother also
has experienced persistent microscopic hematuria.
Patient 2. A 46-year-old man was referred to us soon after the diagnosis
of IgA nephropathy had been established by renal biopsy. Microscopic
hematuria and mild proteinuria (600—800 mg/day) had persisted for 5
years before the renal biopsy. In addition, he had been slightly hyperten-
sive (150/100 mm Hg). At the time of the biopsy, he was in apparent good
health, and physical examination revealed no discernible abnormality, save
that his blood pressure was 145/100 mm Hg and ophthalmologic evalua-
tion revealed grade-i retinopathy; audiologic examination was normal.
Laboratory findings were: glucose, 89 mg/dl; BUN, 20 mg/dl; serum
creatinine, 1.1 mg/dl; creatinine clearance, 140 mI/mm; sodium, 143
mEq/liter; potassium, 4.3 mEq/liter; chloride, 104 mEq/liter; bicarbonate,
25 mEq/liter; calcium, 8.9 mgldl; phosphate, 3.0 mg/dl; uric acid, 7.7 mg/dl;
total protein, 7.0 g/dl; albumin, 3.5 g/dl; cholesterol, 234 mg/dl; triglycer-
ides, 96 mg/dl. The 24-hour urinary protein excretion was 950 mg.
Urinalysis revealed numerous eiythrocytes but no white cells or fatty casts.
Immunologic studies revealed normal serum levels of IgG, 1gM, C3, C4,
and factor B and an elevated value of IgA (515 mg/dl). Ultrasonography
showed two normal kidneys.
Light microscopic evaluation of the biopsy specimen revealed mesangial
cell proliferation with focal and segmental lesions; adhesions and small
crescents were present in some glomeruli. Twenty percent of the glomeruli
were obsolescent. Mild focal interstitial edema and infiltrates were found.
Immunofluorescent microscopy revealed moderate IgA and C3 mesangial
deposits; similar deposits also were found in the capillary walls of some
glomeruli.
Over the following 10 years, his blood pressure has been well controlled
by enalapnil, 10 mg twice daily. Proteinuria ranges between 450 and 1000
mg/day.
The patient's sister developed hypertension at age 43 (160/110mm Hg);
microscopic hematuria and mild proteinuria (500—1000 mg/day) were
noted. A renal biopsy revealed mesangial cell proliferation in less than
50% of glomeruli, rare areas of sclerosis and adhesions, mild tubular
atrophy, and interstitial infiltrate. Immunofluorescent microscopy re-
vealed mild mesangial and parietal deposits of IgA, 1gM, and C3. The
patient's daughter was found to have intermittent microscopic hematuria
(Fig. 1).
No members of either of these two patients' families had deafness or
ocular defects.
Discussion
DR. F. PAULO SCHENA (Chairman, Institute of Nephrology, and
Professor of Nephrology, University of Bari Polyclinic, Ban, Italy):
These case reports describe two families, each of which had two
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Fig. 1. Pedigrees of 2 families with pIgAN.
Upper panel: family from Patient 1. Lower
panel: family from Patient 2. Black symbols
indicate affected individuals; open symbols
indicate unaffected individuals; hatched symbols
indicate individuals with persistent
microhematuria. A line through the symbol
indicates deceased members. Arrows indicate
probands.
siblings with clinical and renal biopsy-proven primary IgA ne-
phropathy (pIgAN), or Berger's disease, and other members with
persistent microhematuria. Primary IgA nephropathy is charac-
terized by persistent hematuria and mesangial deposits of IgA on
renal biopsy in the absence of any recognizable systemic disease
(for example, lupus erythematosus, Henoch-Schönlein purpura,
cryoglobulinemia) or liver disease [1]. Worldwide, pIgAN is the
most frequent cause of glomerulonephritis among patients who
undergo renal biopsy. For example, in Asia pIgAN accounts for
29.2%; in Australia, 12%; in Europe, 10.7%; and in North
America, 5% [2]. The differences in the prevalence of primary IgA
nephropathy in different geographic regions of the world might be
due to differences in renal biopsy policies and in the use of
urinalysis in health screening.
The concept that the documented prevalence of pIgAN is
influenced by the local policy for renal biopsy is supported by data
from Scottish nephrologists [3]. Propper et al pointed out that the
4% prevalence of pIgAN, previously reported by Sissons et al [I,
was based on renal biopsy data from symptomatic patients. In
contrast, Propper and colleagues demonstrated pIgAN in 37% of
individuals with asymptomatic hematuria who underwent renal
biopsy [5]. Thus, it is misleading to compare the prevalence of
pIgAN among various regions of the world unless the indications
for renal biopsy are taken into consideration.
Differences in utilization of screening urinalysis also strongly
influence the reported prevalence of pIgAN. In fact, in Asia, there
are large differences among Japan, Singapore, Korea, and Hong
Kong because in 1973 the Japanese School Health Law imposed
routine urinalysis screening for all school children [6, 7]. In
Singapore, army recruits have a regular medical examination, and
individuals with recurrent micro- or macrohematuria undergo
renal biopsy [81. In conjunction with the frequent use of renal
biopsy in subjects with recurrent microscopic, as well as macro-
scopic, hematuria, such screening likely contributes to the ob-
served high prevalence of pIgAN in Asia.
In Italy, the Italian Immunopathology Group, which collected
data from 45 nephrology centers for the Renal Biopsy National
Registry, found major differences in the prevalence of pIgAN;
rates ranged between 10% and 40% of all renal biopsies per-
formed in one year. The mean value of 22.6% in 1987 [9] was
similar to that observed in 1991 (19.4%) among 2036 renal
biopsies examined [10]. In our Division, the percentage of pIgAN
in the renal biopsies in the last 4 years ranged between 20% and
28.6%. Interestingly, using the classification scheme proposed by
Lee et al [11] and comparing renal biopsy reports of 1990 and
1993, we found an increased frequency of patients with mild renal
lesions (GI and G2), from 33% to 61%, a slight increase of
patients with moderate renal damage (G3), from 16% to 24%,
and a reduced percentage of patients with severe renal lesions,
from 50% to 15%. These data presumably fit with the progressive
liberalization of our renal biopsy policy during the last 4 years.
The weighted mean length of followup (2—S years) obtained
from different studies [2] after the performance of renal biopsy
showed decreased renal function in 23% of the patients, but the
percentage of patients with renal dysfunction rose to as high as
50% after 20 years [11]. Because pIgAN appears mainly in
patients between 10 and 30 years of age and is a slowly progressive
glomerulonephritis with a high prevalence of chronic renal insuf-
ficiency and/or end-stage renal disease, this disease clearly has
important social and public health implications. Due to its high
prevalence, I believe that a program of routine urinalysis screen-
ing in schools and workplaces, followed by an appropriate renal
biopsy policy, should be adopted.
The clinical features of pIgAN have been well described by
many investigators [2, 12]. Microhematuria, typically the first
symptom of the disease, occurs more frequently in Asia (67.4%)
than in Europe (39.5%), North America (38.1%), and Australia
(30.2%). Macroscopic hematuria is more frequent in North
American, Australian, and European patients with pIgAN (56%,
46.5%, and 39.7%, respectively) than in Asian patients (11.5%).
Only a small percentage of patients present with mild pro teinuria
(13%), nephrotic syndrome (2.8% to 6.4%), and/or arterial
/
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Table 1. Immunogenetic associations on the sixth chromosome in patients with pIgAN from several geographic regions
Reference
No. Country
No. of
patients
No. of
controls
Antigen
association
Frequen
Patients (%)
cy in
Controls (%) P values Relative risk
HLA-A, B, C
13 Australia 13 — Bw35 46 — — —
14 France 29 591 Bw35 48 19 0.005 3.9
15 France 43 105 Bw35 39 13 0.02 4.2
16 UK 17 210 Cwl 29 4 0.05 10.5
17 USA 17 100 B12 59 20 0.05 5.7
18 Japan 24 139 Bw44 33 9 0.01 4.8
19 Japan 130 472 Bw35 30 15 0.02 2.3
HLA-D
20 Japan 40 115 DRw6 46 18 0.02 3.8
21 France 37 — DRw4 43 13 0.01 —
22 France 45 113 DR4 49 19 0.001 3.9
23 UK 46 385 DR1 49 24 0.008 2.5
18 Japan 24 64 DR4 66 29 0.001 4.7
24 Japan 104 135 DR4 60 36 0.02 2.6
25 France 58 — DR4 41 19 0.01 —
26 Japan 70 100 DR4 58 34 0.03 2.7
19 Japan 130 472 DR4 60 41 0.01 2.1
HLA complement
27 USA 48 102 C4 15 4 0.04 4.2
28 USA 141 117 C4 12 5 0.05 2.5
29 W. Germany 67 50 Bf 10 0 0.05 5.8
hypertension (7.6% to 15%). In the remainder of this Forum, I
plan to focus on the immunogenetic and familial aspects of pIgA
nephropathy.
Immunogenetic associations
Studies on the role of genetics in pIgAN began in the mid-
1970s, when investigators described a strong association between
this disease and the HLA BW35 antigen [13—15]. These reports
were followed by contributions from other countries (Table 1),
with indications of a strong association between some HLA
antigens and pIgAN [16—291. The discrepancy among these
studies might be due to differences in the selection of patients and
differences in the genetic makeup of different countries. In fact,
the HLA antigen association varied from country to country and,
in some countries, from area to area. In addition, it is likely that
more than one gene determines susceptibility to the disease;
conversely, the effects of these genes could be modified by
environmental factors in the population. Of particular interest is
the report of a strong association between HLA-DR4 and pIgAN,
in which the relative risk ranged between 2.1 and 4.7 [18, 19, 21,
22, 24—26]. Because the DR locus appears to influence various
aspects of humoral and cellular immune response—particularly
the efficiency of interaction among T-cells, B-cells, and macro-
phages—the sequence of immunologic processes in pIgAN likely
is genetically controlled by the HLA-DR genes. Several findings,
such as high serum levels of IgA [mainly in polymeric (p) form],
high levels of IgA-bearing cells and an increased in-vitro sponta-
neous production of IgA by peripheral blood mononuclear cells
(PBMC), argue in favor of an abnormal IgA immune response in
pIgAN. Several investigators who studied the influence of DR4
antigen on the deterioration of renal function in patients with
pIgA nephropathy reported conflicting data [18, 19, 30]. Other
investigators have suggested that C4 genes could contribute to
susceptibility to the disease [27, 28].
Traditionally, HLA typing is accomplished by serologic or
cellular techniques that require the presence of detectable levels
of HLA proteins on the lymphocyte surface. The recent applica-
tion of HLA polymorphism analysis at the genic level has over-
come the limitation of traditional typing methods [31]. In fact,
some alleles do not contain a unique sequence and must be
identified with a combination of probes that detect sequences
present in two or more alleles. Three class-lI products, DP, DO,
and DR, are crucial for presentation of processed antigen to
specific T-cells. Each class-Il antigen is a heterodimer consisting
of a and f3 chains, which are encoded by A and B genes,
respectively. In the last 4 years, several investigators have studied
the gene polymorphism of these class-IT products in patients with
pIgA nephropathy (Table 2). Moore and colleagues demonstrated
that polymorphic variations of the DP region genes were not
important in conferring susceptibility to pIgAN or in influencing
disease expression [32], but a close association of DQB1 with the
disease was found in Caucasoid British patients [33, 34]. Specifi-
cally, Li et al reported an increased frequency of the DQw7
(formally called DQ7) in Caucasoid patients with pIgAN (75%)
compared with controls (28%) [34]. The same investigators
recently described a high frequency of homozygous DO3b(DQ7)
in Chinese patients with pIgAN [35]. Abe and coworkers observed
an increased frequency of DOB (D0w4/8/9) and D-DR4 (DR4)
in Japanese patients with pIgAN and Henoch-Schönlein purpura
[36]. Rambausek et al performed a similar study in patients with
pIgAN but found no increased frequency of DQB-1 (DQw7) [37].
In light of these findings, the putative gene(s) could reside within
or adjacent to the DO and DR subregions. Therefore, a linkage
disequilibrium between the DR and DQ loci, in which DO alleles
can be inherited more frequently together with certain DR alleles,
could contribute to susceptibility to the disease.
If the disease-causing gene is located close to an HLA mole-
cule-encoding gene, a family study would be the most convenient
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Table 2. Genotypic studies on HLA-D loci in patients with IgAN
Reference
No. Yr Pts Race
Ethnic
group Methods
HLA P
value rraDP DO
33 1990 73 Caucasoid British RFLPs DQJ3 0.0001 5.5
34 1991 36 Caucasoid British RFLPs + ASO DQw7 0.001 6.2
32 1992 213 Caucasoid British
Italian
Finnish
RFLPs ns
37 1992 67 Caucasoid German RFLPs DQo1A 0.005 2.6
35 1994 79 Oriental Chinese RFLPs + SSP DQ/33b
DQA2 U (CRF)
DQcr2 (CRF)
DOn2 (NRF)
0.01
0.0003
0.03
0.03
3.2
5.4
0.2
4.1
a rr = relative risk; CRF = chronic renal failure; NRF = normal renal function; RFLP = restriction fragment length polymorphism; ASO =
allele-specific oligonucleotide typing; SSP = sequence specific primers typing.
and likely the only way to identify the association. Three different
approaches can be used to identify an HLA gene marker coseg-
regating with pIgAN. The first is the lod score analysis, which can
individualize the mode of inheritance and penetrance. The second
is the "affected-only" analysis, which is used to determine whether
nonaffected individuals might obscure potential linkage. This
approach is independent of penetrance, and all individuals who
are not coded as affected may be recorded as unknown. A linkage
software package (LINKAGE) [38] is used for these approaches.
The third approach is the "affected-pedigree-member" method,
which does not depend on the mode of inheritance of the disease
and is used because the results of the first two approaches are
subject to inaccuracies in the assumed genetic model. This third
method tests for excess sharing of alleles at the marker locus
among related affected individuals but does not necessarily trace
the segregation of alleles with a disease in families. This method
allows one to evaluate allelic identity-by-state among affected
individuals. The specific genetics program packages (APM-
MULT-version 2.0 and SIMMULT) are used for this method [39,
40]. However, for these studies, it is necessary to collect many
"multiplex" families, that is, families in which two or more
members have biopsy-proven pIgAN.
Family studies
After the first report by de Werra et al in 1973 on the possible
presence of relatives with presumed pIgAN (unfortunately these
cases were not documented by renal biopsy) in a family of a
patient with IgAN [41], other larger familial studies were per-
formed by Egido and colleagues [42] and later by Levy and
Lesavre [43]. Affected members of these families were either
parent and a child, or two or more siblings. In addition, other
relatives frequently had other types of glomerulonephritis, mainly
Henoch-Schönlein purpura. Thus, some family members can have
mild urinary abnormalities, such as persistent microhematuria
and/or proteinuria, whereas others manifest recurrent macrohe-
maturia or chronic renal failure. Of course, renal biopsy is an
entirely appropriate diagnostic approach in the latter group, but
in the former, histologic evaluation of renal involvement typically
is not performed. Two factors militate against genetic studies in
family members of patients with IgAN. First, investigators are
disinclined to perform renal biopsy on family members presenting
with only minimal urinary findings. Although the biopsy is neces-
sary to define the immunohistologic pattern of pIgAN, its invasive
nature makes it unjustifiable. Second, the resistance to performing
renal biopsy on sporadic patients with occasional episodes of
micro- or macrohematuria clearly reduces the possibility of ge-
netic studies.
The true incidence of familial pIgAN is unknown because few
renal units systematically examine the urine of family members
and perform renal biopsy in those individuals with persistent
microhematuria. The more distant relations of patients with
pIgAN were studied in the USA and Italy [44, 45]. In the first
study, 60% of patients from eastern Kentucky were related to at
least one other patient. Epidemiologic investigations did not
reveal a common environmental factor; occupation, type of
residence, and food differed. In the Italian study, a familial
clustering of several cases of chronic glomerulonephritis in pa-
tients belonging to three related families was reported. The higher
gene frequency (of HLA-Dw 8.1, related to DRB8, DQ3a, and
DQalb) in the affected and unaffected pedigree members than in
Italian controls, suggested that these patients had inherited a
susceptibility to develop mesangial glomerulonephritis. Other
unknown factors likely act in concert with the basic genetic
predisposition.
We had the opportunity to study 269 asymptomatic, first-degree
relatives from 48 families of patients with documented pIgAN
from three generations [46]. Microhematuria and proteinuria
were sought by N-Multistix (Ames, Miles, Elkhart, Indiana) on
urine specimens collected at least three times in three months.
When the microhematuria persisted, urine sediments were exam-
ined under the microscope and an Addis count was performed.
Patients with persistent microhematuria underwent renal echoto-
mography. Interestingly, some young family members who had
shown a negative urinalysis at the beginning of our study devel-
oped microhematuria later during the course of our investigation
(2 years). Urinalysis revealed persistent microhematuria in 42 of
269 relatives (15.6%), persistent proteinuria in 8 members (3%),
and both abnormalities in 11 relatives (4%) (Fig. 2). Twenty-two
families had 2 or more members with urinary abnormalities, and
6 families had one member with persistent microhematuria or
proteinuria. Finally, biopsy-proven pIgAN was documented in 4
relatives who had urinary abnormalities. We compared the prev-
alence of urinary abnormalities among the relatives of affected
individuals with that in a large number of young people from the
general population (8255 students who ranged in age between 6
and 18 years) and found a significant difference: only 4.3% of
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Table 3. In-vitro 1gM and IgA production by peripheral blood
mononuclear cells of pIgAN patients and their relatives [54]'
Controls
(n=18)
Patients
(n = 22)
Relatives
With
microhem.
(n = 12)
Without
microhem.
(n = 32)
1gM
Spontaneous
prod.
Stimulated prod.
-Fold increase
472 106
1084 183
2.3 0.7
1012 163"
2557 294"
2.6 0.5
727 175
2625 655h
3.2 0.6
670 106
2572 437"
3.7 0.6
IgA tot.
Spontaneous
prod.
Stimulated prod.
-Fold increase
1262 334
2322 510
1.3 0.3
4115 538"
9124 835"
1.8 0.4
2232 482
8366 1836"
3.4 1.0"
1850 247
7774 788"
4.5 0.6"
IgAl
Spontaneous
prod.
Stimulated prod.
-Fold increase
991 259
2070 508
1.7 0.6
3594 479"
7294 751"
1.7 0.4
1743 490
7347 1600"
4.4 1.2"
1664 239
6578 756"
4.6 0.8"
IgA2
Spontaneous
prod.
Stimulated prod.
-Fold increase
142 45
257 71
1.2 0.3
274 50
465 78
0.8 0.1
175 38
427 104
1.7 0.5
338 122
418 56
1.0 0.2
Immunoglobulin concentrations are expressed in ng/ml. Values are
mean SEM. The mean-fold increase for each group is the mean of the
-fold increases of the individual samples.
hSignificant difference (P < 0.05, ANOVA) compared to control group.
Fig. 2. Incidence of urinaly abnormalities in 269 relatives from 48 families of
patients witi, pIgAN (A) and in 8255 students (B). Symbols are: ()
microhcmaturia; () proteinuria; (El) microhematuria + proteinuria; (U)
normal urine.
students had persistent urinary abnormalities (2%, microhematu-
na; 2%, proteinuria; and 0.3%, microhematuria and proteinuria)
(Fig. 2) (Aquilino A et al, unpublished data). In conclusion, our
study demonstrated that urinary abnormalities occurred in 22.6%
of relatives of patients with pIgAN. Thus, nearly one-quarter of
family members might be affected by pIgAN or other mesangial
glomerulonephritides.
Phenotypic serum abnormalities in relatives. Several investigators
have shown various abnormalities in the immune regulation of the
IgA system in patients with pIgAN and their relatives [47—52]. We
studied phenotypic serum abnormalities in 54 of 120 first-degree
relatives of 11 patients with IgAN who belonged to 9 unrelated
pedigrees [53]. Of 54 relatives, 36 (66%) had at least one serum
IgA abnormality (high levels of lgA, pIgA, IgA rheumatoid factor,
or circulating IgAl/lgM or IgAl/IgG immune complexes), and 15
of 54 relatives (27%) showed more than one abnormality. More-
over, serum IgA abnormalities were present in 9 of 13 family
members who had persistent microhematuria (69%).
When age distribution was taken into account, 53% of relatives
younger than 18 years had serum IgA abnormalities; the fre-
quency rose to 69% in family members between 19 and 40 years,
and to 85% in those between 40 and 60 years. In older relatives
(>60 years), 62% had serum IgA abnormalities. The serum levels
of pigA were higher in patients with pIgA nephropathy and in
their relatives who either had microhematuria or no urinary
abnormalities than in controls. High values of 1gM also were
found in patients with IgAN and their relatives regardless of the
presence of urinary abnormalities. Serum levels of IgG were not
significantly increased. These findings confirm the high frequency
of serum IgA abnormalities in relatives of patients with pIgAN.
However, it is interesting to note that high serum levels of 1gM
also were present in relatives.
We also investigated the in-vitro immunoglobulin synthesis by
peripheral blood mononuclear cells (PBMC) in a relatively small
number of relatives (39 subjects); blood samples from children
were not available in our studies [53, 54]. High pokeweed mitogen
(PWM)-induced cell production of IgA, IgAl, and 1gM, pigA,
and IgA rheumatoid factor was found in 64% of relatives from 8
families. The production increased both in relatives with urinary
abnormalities and in those with normal urinalyses (Table 3). No
difference in basal or stimulated production of IgG and their
subclasses was found [54]. Our findings [54], in agreement with
those reported by others [55, 56], demonstrate that the increased
production of IgA is restricted to the subclass Al. Investigators
now agree that IgAl represents the predominant subclass of
immunoglobulins in mesangial deposits of pIgAN and in circulat-
ing immune complexes [57, 58]. Increased IgAl-producing plasma
A
15.69
4%
3%
95.7%
B
2%
Nephrology Fomm: Immunogenetics and IgA nephropathy 2003
'>IL-4
CD4O
ligand CD4O
cells have been described in tonsils and bone marrow of patients
with pIgAN [59, 60]. A dysregulation of the IgAl, and not the
IgA2, system is thus well established as a contributor to some
pathogenetic aspects of pIgAN. We also confirmed reports by
Hale et al [61] and others [62, 63] concerning high serum levels of
1gM and abnormal production of this immunoglobulin by stimu-
lated PBMC in relatives [53].
On the basis of these findings, one can hypothesize that a
common genetic substrate affects B-lymphocyte function in pa-
tients and their relatives. It is noteworthy that PBMC isolated
from relatives showed an increased mitogen-induced synthesis of
IgA and IgAl when compared with controls and even with
patients. Asymptomatic and unaffected relatives lack the sponta-
neous hyperproduction of IgAl and 1gM that specifically charac-
terizes the patients, however. Thus, the reduced suppressor
activity claimed to explain basal IgAl and 1gM hyperproduction in
patients with pIgAN may be superimposed on a general hyperac-
tivity of specific IgAl and 1gM production in relatives, as revealed
by in-vitro stimulation with mitogens.
Cytokine production by PBMC of relatives. Our findings, as well
as those of other authors regarding abnormal production of IgA in
patients with pIgAN and their relatives, support the view that the
imbalanced regulation of immunoglobulin synthesis is not limited
to an altered switch from 1gM to IgAl production, but involves a
more complicated imbalance in the regulation of IgA synthesis
[53, 54, 62—65]. An altered production of cytokines might play an
important role within this framework, given recent evidence
suggesting that IL-2, IL-4, IL-5, IL-6, IL-b, and TGF/3 regulate
immunoglobulin isotype production [66—69] (Fig. 3). In addition,
other investigators also have reported a role for IL-12 and IL-13
[70, 71].
We studied the spontaneous and mitogen-induced production
of some of these cytokines by PBMC from 34 patients with pIgAN
and 44 of their first-degree relatives, 10 of whom had persistent
microhematuria [72]. Peripheral blood mononuclear cells from
Fig. 3. Specific cytokines implicated in
modulating the Ig class switch process.
Abbreviations: Thc (T-helper cell); Bc (B-cell).
patients and relatives with microhematuria showed increased
spontaneous production of IL-2, whereas IL-4, IL-6, and IFN-y
production were normal. Phytohemagglutinin stimulation in-
creased production of all the cytokines tested [72]. Interestingly,
relatives of pIgAN patients with microhematuria had the same
profile of cytokine production as did patients with pIgAN. Con-
versely, relatives with normal urinalyses did not display any
significant difference in cytokine synthesis from normals (Table 4).
We [73] and others [74—77] observed an overproduction of
cytokines (IL-2 and others) in patients with pIgAN, whereas such
hyperproduction of T-cell cytokines was not found in patients with
other forms of glomerulonephritis. In addition, we demonstrated
that this aberrant cytokine synthesis also was present in patients'
relatives with microhematuria [72].
Some of these cytokines play a key role in immunoglobulin class
switching and influence the synthesis of IgA and IgE by PBMC
from patients with pIgAN [63, 78]. Thus, an abnormally high
production of these cytokines could favor an imbalance in the
distribution of isotypes in antibody responses in patients and
relatives. Such an imbalance, expressed as a loss of mucosal
tolerance, might underlie defects in the population of antigen-
specific IgA+ cells in the mucosal lamina propria, promoting
antigen penetration of the mucosal barrier [79—81].
IgMilgA switch and cytokine regulation
Immunoglobulin class switch recombination allows B-cells to
sequentially express antibodies that have identical specificities but
that differ in class and thus in effector function. Isotype switching
requires collaboration between antibody-synthesizing B-cells and
helper CD4+T cells. B-cells first express antibodies of the 1gM
and IgD isotypes on the plasma membrane. During the primary
immune response, 1gM is the predominant isotype expressed, the
secondary immune response being characterized by a switch to
one of the other immunoglobulin isotypes (IgG/IgA). The end
result of isotype switching is the production of antibodies that use
1gM
1gM
IL-i 0
IL-2
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Table 4. In-vitro cytokine production by peripheral blood mononuclear cells of pIgAN patients and their relatives [72]'
Controls
(n = 34)
IgAN patients'(n = 34)
Relatives
Other GN
(n 17)
With microhematuria
(n = 10)
Without
microhematuria
(n = 34)
IL-2
Spontaneous
Stimulated
62 5
626 55
121 14C
1274 168"
115 22'
1153 210"
86 11
730 100
94 23
1017 191
IL.4
Spontaneous
Stimulated
64 4
211 26
76 5
574 98"
70 8
519 148"
62 4
310 55
73 13
313 69
IL-6
Spontaneous
Stimulated
1082 181
22957 1501
1727 191
27142 1814
1977 405
26786 2481
1347 282
23750 905
1996 382
25640 2589
IFN-y
Spontaneous
Stimulated
51 4
243 20
53 5
331 39C
56 9
367 69"
53 4
253 19
57 8
271 45
"Cytokine concentrations are expressed in pg/mi. Values are mean SEM.
b IgAN, IgA nephropathy; GN, glomerulonephritis.
C Significant difference (P < 0.05, ANOVA) compared with control group.
I_Ill 111111 liii LI_LLLLL
deletion
VDJ joining
C, C,
S'y2 S72a
Cu1 Cct2
VDJ Sit-a1 Sa2
Fig. 4. Heavy chain gene assembly throughout the deletion mechanism and two successive switches (Sp.-Syl recombination and Sji-Sal recombination).
Abbreviations: V, variable; J, joining; D, diversity; 5, switching.
the same V (variable) region and therefore have identical antigen-
binding properties, but which use a new C (constant) region. Due
to isotype switching, the four IgG subclasses predominate in
serum, while IgA is prominent in mucosal secretion. The V, D
(diversity), and J (joining) gene segments are juxtaposed in frame
and together encode the variable domain of the immunoglobulin
heavy chain. The constant domains of the immunoglobulin iso-
types are encoded by C genes located 3' to C/k on the same
chromosome 14. The formation of VDJ gene and isotype switch-
ing each involve DNA recombination. VDJ recombination is
targeted by highly conserved sequences; switch recombination can
occur at multiple sites throughout noncoding S (switching) re-
gions (Fig. 4). DNA rearrangement during class switching of
heavy genes occurs via an intramolecular looping out-deletion
mechanism that generates a circular DNA excision product.
Three gene families localized on chromosomes 2, 14, and 22,
respectively, control the organization and expression of the heavy
and kappa and lambda light chains of the immunoglobulins.
V genes D segments J segments
300 10 4
F'e— C genes
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Because the polymorphism of the immunoglobulin heavy chain
switch region genes is associated with differences in the variable
heavy chain region, alterations in the Sjt and Sa gene regions
probably influence the immunoglobulin heavy chain switch region.
The first report on the switch region sequences in patients with
pIgA nephropathy showed differences for the Sj and Sal geno-
type and phenotypes that control the antigen recognition reper-
toire [82]. A significant increase in the Sal genotype number was
observed in English and German patients with pIgAN. These
results suggested that genes within the immunoglobulin heavy
chain loci may play an important role in the pathogenesis of
pIgAN. However, Moore et a!, in a similar study performed in
pIgAN patients from the UK, Finland, and Italy, did not confirm
the significant differences in the genotypic frequencies of S and
Scr alleles [831.
Three cytokines (IL-4, IL-5, and TGFI3) play pivotal roles in
regulating the IgA switch process. Specifically, in humans, TGF/3
appears to be an IgA-specific switch factor; moreover, IL-6 also
might be implicated in the switch mechanism. These cytokines
induce the production of specific immunoglobulin isotypes by
altering the chromatin state and inducing the transcription of the
constant heavy (CH) genes to which they direct switching. IL-4
stimulates accumulation of germline transcripts, IFN-y induces
accumulation of germline y2a transcript, and TGFP induces
accumulation of germline a transcripts [67]. The accumulation of
germline transcripts appears to be a very early event in isotype
switching. The cytokines may target specific switch regions for
DNA recombination by regulating their accessibility to a switch
recombinase. However, a second signal is necessary for isotype
switching. CD4O is required for completing isotype switching to
IgE, while IL-S provides for isotype switching of IgGi, IgE, and
IgA.
Recent genetic studies on diseases caused by primary hyperim-
munoglobulinemia have shown that the IL-4 gene is a major
candidate for IgE responsiveness and atopy [84], the CD40 ligand
gene defect is responsible for X-linked hyper-IgM syndrome [85],
the deficient local IgA response is found in mice with targeted
disruption of the gene encoding IL-6 [86], and impaired immune
and acute phase responses occur in the IL-6-deficient mouse [87].
The restoration of the IL-6 gene improved the IgA antibody
response. Moreover, the evidence of an impaired IgA switching
has been reported in patients with IgA deficiency [88]. These data
suggest that investigating the gene expression of TGFI3, IL-4,
IL-5, and IL-6 in patients with pIgAN might help to reveal a
defect of isotype switching.
Approximately 10% of the DNA in the genome consists of
repeats of two nucleotides that are usually approximately 250 base
pairs long. These repeats were originally considered non-coding
sequences, and they were called satellite DNA. The length of each
satellite DNA varies from one person to another; this polymor-
phism can serve as chromosomal markers [89]. Some short runs of
tandemly repeated DNA, designated "hypervariable minisatel-
lites," "variable number of tandem repeats," or "variable tandem
repeats," arise from the head-to-tail concatenation of short-
sequence motifs 10 to 100 bp long. These arrays, through a
mutational process that increases or decreases the number of
repeat motifs in a given allele, are frequently unstable and
produce highly polymorphic loci that often possess dozens of
alleles. Other short runs of tandemly repeated DNA are the
"microsatellites" that are sequence motifs 1 to 6 bp long. Conse-
quently, mini- and microsatellites are ideal genetic markers for
the investigation of a wide range of genetic variations. Recently,
these short runs of tandemly repeated DNA have been observed
in cytokine genes such as IL-4 and IL-6 [90, 91]. Polymorphisms
for the TGF gene, which codifies for the specific cytokine of the
IgA switch process, have not yet been reported. By using the DNA
satellites, however, it is possible to analyze the linkage of some of
their cytokine polymorphic markers to pIgAN in affected families.
Is pIgAN a familial disease?
The occurrence of pIgAN aggregates in some families in which
about 25% of first-degree relatives have biopsy-proven IgAN or
persistent microscopic hematuria and/or proteinuria and in which
over 66% of relatives have immunologic abnormalities of the IgA
system [53] (which might depend on altered cytokine production)
suggests that pIgAN may be an inherited disease. A genetic
background responsible for the observed abnormalities could
interact with environmental factors during life and promote
development of the disease. An additional argument in favor of
pIgAN being an inherited disease is the existence of the large
pedigrees in which many pIgAN patients in several generations
have been reported in various parts of the world [44, 45, 92].
Arguments against this hypothesis are: (1) genotyping studies
have not shown that HLA antigens uniformly cosegregate with
pIgAN, and (2) families with several members affected by pIgAN
have not evidenced the same Mendelian inheritance pattern.
Many obstacles hinder the evaluation and design of genetic
studies of pIgAN. First, the occurrence of multiple pathogenetic
mechanisms—such as primary B- or T-cell hyperactivity, primary
lymphokine hyperproduction, and others—indicate a probable
polygenic disease. Second, environmental factors, such as diet and
exogenous antigenic challenge, might play a major role in the
pathogenesis. Therefore pIgAN might be caused by the interac-
tion of environmental factors with several genes at different loci,
each of them with an additive effect. Finally, despite an increasing
awareness of the familial and regional clustering of patients with
pIgAN, no true serologic marker is available. The diagnosis
therefore requires renal biopsy, an invasive procedure especially
hard to justify in apparently healthy subjects whose only abnor-
mality is persistent microhematuria and/or asymptomatic, mild
proteinuria.
The two general approaches to uncovering the molecular basis
for a polygenic disease are: (1) seeking a "candidate gene" and (2)
performing a "blind hunt" with batteries of probes for single-point
restriction fragment length polymorphisms or hypervariable re-
gions [93]. Candidate genes for pIgAN are as various as those
encoding inimunoglobulins, complement proteins, T-cell recep-
tors, cytokines, and some antigens of the major histocompatibility
complex. The data in the IgAN literature indicate that this
disease, characterized by polymeric IgAl renal deposits with A
chain, has four fundamental aspects. First, the serum contains
both high levels of IgA, mainly A-IgAl with anionic charge and in
polymeric form, and increased numbers of IgA-bearing B-lympho-
cytes and activated Ta helper cells (CD4+ and IL-2r+). Second,
some "immunologic-rich" tissues such as tonsils and bone marrow
produce abnormal amounts of IgAl. Third, cultured peripheral
blood lymphocytes produce increased amounts of A-IgAl and
cytokines (IL-2, IL-4, IL-5, IL-6, TGFp, and IFN-y). Finally,
recent studies of CD4+ cells from patients with IgAN have shown
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augmented mRNA expression of those cytokines (IL-4 and
TGFI3) that are devoted to regulating the IgA switch process [94].
On the basis of these findings, I think it would be worthwhile to
study the genetic variations of the factors that regulate the
immunoglobulin class switch process in IgAN patients and their
relatives. These studies should be done in large, multiple-gener-
ation families using the "sib-pair" analysis, which consists of
comparing affected with non-affected siblings. Studies of twins
should be especially useful in defining the genetic component of
pIgAN.
Conclusions
The study of classical genetics focuses on dominant and reces-
sive diseases, whereas the study of genetics at the molecular level
entails a much more complicated set of genotype/phenotype
associations. Awareness is growing that the clinical risk for a given
disease stems from the interaction between susceptible genotypes
and deleterious environmental factors. I think pIgAN is one of
those diseases. Although the genetic structure underlying IgA
production remains constant throughout life, specific genes are
probably developmentally regulated so that their influence on IgA
production is expressed only at a certain age. We observed that
some relatives of patients with pIgAN initially have negative
urinalyses but develop microhematuria years later. Moreover,
abnormalities in serum IgA appear to increase with age in
relatives of affected patients. Thus, the expression and activity of
the IgA system in the families might be modulated by the
combined interaction of a number of genetically influenced
intermediate phenotypes, each acting with environmental factors
(for example, infections, dietary antigens). Some of these envi-
ronmental factors could be transmitted within family units; other
factors could be randomly dispersed throughout the population.
The principal approach in revealing the genetic factors should
consist in (1) identifying the intermediate phenotypes, which have
a strong genetic component, and (2) applying molecular tech-
niques to identify the genotypes. The distribution of the identified
genotypes within high-risk pedigrees will subsequently allow us to
determine how they interact and whether they can be used as
pre-clinical markers of susceptibility to pIgAN. Much more work
is needed to identify a substantial number of genotypes and to
understand how each contributes to inducing pIgAN.
Questions and answers
DR. NIcoLAos E. MADIAS (Chief Division of Nephrology, New
England Medical Center, Boston, Massachusetts): Is there any
evidence that progression to renal dysfunction is different in
familial versus nonfamilial cases of IgAN? Do any hereditary
features appear to predict progression?
DR. Sd-lENA: Two groups of nephrologists, Egido et a! in Spain
[42, 48] and Julian et al in the US [50], have investigated whether
the clinical manifestations of pIgAN in patients with familial
disease differ from those of patients with sporadic pIgAN. Both
groups concluded that clinical findings cannot distinguish the two
groups; the mean age at onset of the disease, age at the time of
renal biopsy, degree of microhematuria, and daily proteinuria
were similar. In contrast, immunologic abnormalities of the IgA
system were more evident in familial IgAN. Thus, there is a
genetic predisposition to these IgA abnormalities, but that does
not predict the outcome of the disease.
DR. LANDINO ALLEGRI (Institute of Medical Clinic and Nephrol-
ogy, University of Parma, Parina, Italy): You mentioned in your
presentation that many studies had found IgA nephropathy in
first-degree relatives of affected patients. What is the prevalence
of IgA nephropathy in your own experience?
DR. SCHENA: Unfortunately, I do not have a precise answer to
your question. In a previous study, we performed urinalyses in 54
first-degree relatives of 9 unrelated pedigrees of pIgAN patients
[53]. The relatives were distributed over three generations, and
persistent microhematuria was found in 24% of subjects. In the
last 3 years, we expanded our familial study, analyzing urine of 275
relatives of 50 unrelated pedigrees. We found persistent micro-
hematuria in 25% of the relatives. Interestingly, microhematuria
was most prevalent in the second and third decade. Given the
invasive nature of renal biopsy, IgAN was documented by renal
biopsy only in 5 relatives.
DR. JEROME P. KASSIRER (Editor-in-Chief New England Journal
of Medicine, Boston, Massachusetts): It seems to me that your own
conclusions about the genetic and environmental influences of
IgA nephropathy contradict your earlier conclusions about the
explanation for the difference in prevalence of IgA nephropathy
in various parts of the world, biopsy practices, for example. Unless
the genotype frequency is the same in India, Europe, and the
USA, which seems quite unlikely, the two conclusions appear to
contradict each other.
DR. SCHENA: The contradiction is only apparent. Indeed, dif-
ferent biopsy policies can amplify differences due to genetic
and/or environmental factors. If we consider some Asian coun-
tries that have adopted a similar renal biopsy policy, we still find
a different prevalence of the disease: 40% in Japan and 52% in
Singapore. Additionally, the same environmental factor can influ-
ence the IgA system in a different way, as shown by a recent
multicenter study. Coppo et al demonstrated that sera of pIgAN
patients from Italy, Australia, and Japan had different patterns of
IgA immune complexes, IgA antibodies against dietary antigens,
and also a different lectin-binding activity of IgA [951.
DR. GREGORY G. VOSNIDES (Chief Division of Nephrology,
Laiko General Hospital, Athens, Greece): Nephritis accompanying
Henoch-SchOnlein purpura shares similarities with IgA nephrop-
athy. In addition, mesangial IgA deposits are found in patients
with alcoholic liver disease and in patients with immunologic
diseases, for example, ulcerative colitis and ankylosing spondylitis.
Is there any immunologic or immunogenetic link between these
conditions and idiopathic IgAN?
DR. SCHENA: The occurrence of IgAN and Henoch-Schönlein
syndrome in members of the same family was reported first by
Meadow and Scott [96] and subsequently by others. In a cooper-
ative study, M. Levy and the French Society of Nephrology
collected clinical data from 15 families in which 2 or more
members were affected by pIgAN or anaphylactoid purpura [97].
Cases of IgAN evolving into Henoch-Schönlein syndrome have
been reported by others. These and other diseases share a
common finding, IgA deposition in the glomerular mesangium.
Patients with IgAN can synthesize IgA molecules with an altered
composition consisting of a deficiency of galactose residues in the
hinge region of the IgA [98]; this alteration results in reduced
recognition of this protein by the sialoglycoprotein receptor. A
marked deficiency in galactose residues of IgA1 from patients
with pIgAN might be responsible for inefficient plasma clearance
and persistent mesangial deposition. An analogous alteration
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might be present in the diseases that you have previously men-
tioned.
DR. DANIEL CORDONNIER (Centre Hospitalier Universitaire,
Grenoble, France): Did you obtain blood pressure measurements
in family members of patients with sporadic and familial IgAN?
I'm interested in knowing whether the familial predisposition to
essential hypertension is linked in any way to the familial predis-
position to IgAN.
DR. SCHENA: The frequency of hypertension in pIgAN patients
without renal insufficiency is higher than that found in the healthy
population matched for gender and age and living in the same
geographic area. At the onset of the disease, hypertension is
present in 5% to 10% of patients. At the time of renal biopsy, this
percentage is higher (20% to 30%) and it increases with long-term
followup, during which about 50% of patients become hyperten-
sive [99]. Differences in the prevalence of hypertension between
patients with sporadic IgAN and those with familial IgAN have
not been reported. Additionally, no data have been published on
the prevalence of hypertension in family members of patients with
IgAN. In our family study, we did not measure blood pressure.
However, nephrologists from Heidelberg reported a possible
increased genetic risk of hypertension in patients with chronic
glomerulonephritis; mesangial IgA deposits were found in 0.6%
of post-mortem kidney specimens collected from 337 hypertensive
patients [100, 101].
DR. KOSTAS C. SIAMOPOULOS (Associate Professor of Medicine!
Nephrology, University Hospital of Joannina, Joannina, Greece):
Regarding the progression of IgAN to renal failure, what is your
opinion about the role of interstitial lesions, particularly in
patients with minor glomerular lesions? Have you seen patients
with interstitial lesions more severe than glomerular lesions?
DR. SCHENA: That is an interesting question because the role of
the interstitial lesions in the progression of the renal damage in
pIgAN has been emphasized recently. Interstitial infiltrates are
more frequent in patients with moderate and severe glomerular
lesions (G3—G5) than in those with minimal or minor changes
(G1—G2); Lee's classification of pIgAN takes note of this fact [11].
Moreover, the presence of extensive interstitial infiltrates is a poor
prognostic marker. The interstitial infiltrates comprise monocyte!
macrophages and T-lymphocytes, which produce cytokines and
growth factors in large amounts. The decrease of renal function in
patients during the course of 8 to 15 years of followup correlates
with the presence of tubulo-interstitial damage but not with
glomerular lesions. However, in my experience I have never found
severe tubulo-interstitial lesions in patients with minimal or minor
glomerular changes.
DR. MADIAS: Does a correlation exist between the production
of IgA or cytokines by peripheral blood mononuclear cells and
activity of the disease?
DR. SCI-IENA: We have found an increased number of cells
actively secreting IgG and IgA in patients with pIgAN during the
active phase of the disease, as defined by fever, upper respiratory
tract infection, and macrohematuria [102]. In addition, we de-
tected increased serum levels of lgAl-IgG immune complexes and
an augmented production of IL-2 by peripheral blood mononu-
clear cells during the relapse of the disease [58, 73]. Increased
T-cell activation and cytokine release also have been observed by
other investigators [76, 77].
DR. L. A. VAN Es (Department of Nephrology, Leiden University,
Leiden, The Netherlands): You have concentrated on cytokines
influencing IgA production by peripheral blood mononuclear
cells. Would you elaborate on the role of cytokines within the
kidney itself, especially with regard to progression of disease?
DR. SCHENA: Several studies support the role of cytokines and
growth factors produced by resident, that is, glomerular, endothe-
hal, tubular, and interstitial, renal cells as well as by cellular
infiltrates. Recent experimental studies have shown that cytokines
are responsible for the in-vitro production of some complement
factors, for example, C3 and C4, by mesangial and tubular cells
[103, 104]. Moreover, Montinaro and colleagues demonstrated
that the combination of IL-i and IL-6 intensified mesangial
hypercellularity in a model of experimental IgAN [105]. The
synergy of these cytokines with the nephritogenicity of the anti-
gens could lead to the rapid progression of renal damage. Growth
factors also might be implicated in determining mesangial cell
proliferation in IgAN. We demonstrated an increased glomerular
expression of PDGFI3 receptor in patients with moderate to
severe renal lesions [106].
DR. JEStJ5 EGIDo (Associate Chief of Nephrology, Fundación
Jiménez DIaz, Madrid, Spain): Many relatives of patients with IgA
nephropathy have abnormalities in the regulation of IgA and also
in the synthesis of IL-2 and IL-4. Have you found in a multivariate
analysis any differences between that group of relatives and the
patients themselves? Have you had the opportunity to restudy
patients and healthy relatives?
DR. SCHENA: As I said earlier, the relatives of pIgAN patients
revealed a normal spontaneous production of cytokines, which
increased considerably after phytohemagglutiin stimulation of
PBMC. These findings demonstrate that the relatives of pIgAN
patients are hyper-responsive to stimuli and might produce in-
creased amounts of cytokines during viral or bacterial infections.
When we restudied immunoglobulin production in patients with
pIgAN, we confirmed our earlier results. By contrast, we did not
repeat the cytokine study in relatives, because it is not easy to
obtain collaboration from apparently healthy subjects.
DR. PHILIPPE LESAVRE (Department of Nephrology, Hôpital
Necker, Paris, France): I have two comments and one question.
First, the rare familial cases of IgAN have been studied by
Micheline Levy and the collaborative study group of the Société
de Néphrologie [97]. Familial clustering was more frequent than
previously thought, given that 40 families, each with at least 2
members with biopsy-confirmed IgA nephropathy, were collected.
The main characteristics of the patients were: male predomi-
nance, young age at the apparent onset of the disease, and
severity. Familial cases therefore do not appear different from
isolated cases. The interval between the onset of the disease in
relatives can reach 15 to 30 years, thus favoring a genetic
predisposition rather than environmental factors. In addition, this
study pointed to the links between IgA nephropathy and Henoch-
Schonlein purpura. Both diseases were found in 23 families [107].
Second, together with Micheline Levy, we set up an INSERM
network to study candidate genes in the sporadic form of IgA
nephropathy. HLA-D polymorphism was studied by PCR!oligo-
nucleotide at DQA1, DQB1, and DRB1 loci by Virginia LePage
(INSERM U93, Hôpital Saint-Louis, Paris). No association was
found. Similarly, no association was found with HLA-A, -B, -DR,
or -DQ determined serologically. The HLA-D negative results
were disappointing to us and have not yet been published (Lepage
V, personnal communication). Then Marie Paule LeFranc (URA
CNTS 1191, Montpellier, France) studied RFLP a, /3, y, and
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chains of T-cell receptor (TcR), the constant region of IgG, and K
and y light chain; again, no association was detected. These
negative results were reported only in abstract form during the
11th International Histocompatibility Workshop and Conference
(Yokohama, 1991). The only positive results obtained were ob-
served by studying the RFLP of the alpha switch region using a
switch alpha probe; the patients were characterized by the pres-
ence of new allele fragments not found in the control population.
This finding might be important, because the switch a region gene
precedes the constant domain gene coding for IgA and facilitates
isotype switching. The positive observation was published in
Human Genetics [108]. Don't you think that the immunogenetic
studies are biased by publishing positive results and not negative
results? Do you think that we really have evidence of HLA-D
association in IgAN?
DR. SCHENA: As I mentioned before, many investigators per-
formed phenotypic and genetic studies on the HLA-D region and
obtained different data. In my opinion, these studies are lacking in
two aspects. First, the number of controls, which normally should
be three times the number of IgAN cases, frequently was low.
Second, if the candidate gene is in the HLA-D region or in the
switch a region, it is necessaiy that familial studies be performed
instead of population studies. We are carrying out a similar study
in the families of our patients, and preliminary data are not very
encouraging. Nevertheless, I agree with you that negative results
in this field should be published.
DR. FERNANDO VALDERRABANO (Chairman, Department of Ne-
phrology, Hospital General Universitario Gregorio Maranon, Mad-
rid, Spain): The Spanish Registry of Glomerulonephritis has very
similar data to the Italian Registry. In our last report published in
1994, studying more than 1000 biopsies per year, we found a
prevalence of IgA nephropathy of 22% in adults and 25% in
children among all glomerulonephritides, including the secondary
forms [1091. During the last 20 years, the incidence of IgA
nephropathy has increased simultaneously with the decrease of
membranoproliferative glomerulonephritis without apparent vari-
ations in the criteria for renal biopsies. The last report noted a
decrease in macroscopic hematuria as a presenting symptom of
IgAN [1091. What is your opinion regarding macroscopic hema-
tuna as a prognostic factor in IgAN?
DR. SCHENA: There are contrasting reports on the prognostic
role of the macrohematuria. Some studies have shown that
isolated or recurrent episodes of macrohematuria are more
common in patients with a benign course of the disease. In
contrast, others report gross hematuria as a poor prognostic sign,
since crescents and impaired renal function are often present.
Nicholls and coworkers demonstrated a strong correlation be-
tween hematuria, defined as red blood cells more than 105/ml, and
the presence of crescents [110]. Additionally, in some reports, 3%
of patients with macrohematuric episodes presented with acute
renal insufficiency and red blood cell cast formation in tubules.
The long-term prognosis is poor in these patients when more than
40% of glomeruli are sclerosed.
DR. ALEX M. DAVISON (Consultant Renal Physician, St. James's
University Hospital, Leeds, UK): In view of your findings regarding
the frequency of abnormalities of urinalysis and the immunoge-
netic links between patients and their relatives, would you be
willing to transplant a kidney from an identical twin or another
relative to a patient with end-stage renal failure due to IgA
nephropathy?
DR. SCHENA: Your question is very interesting because pIgAN
is one of the glomerulonephritides that recurs in renal transplant
patients. Let me mention the first report from Berger et al, in
which the recurrence of IgAN was more frequent in patients who
received the kidney from living-related donors (80%) than in
those who received a cadaveric kidney (25%) [111]. These data
favor a familial predisposition to the disease in family members
who develop pIgAN in various periods of their life. The recur-
rence of IgAN has been reported by other nephrologists, who
found a higher recurrence rate of IgAN in recipients of living-
related transplants (83%) when compared with recipients of
cadaveric kidneys (14%) [112]. Therefore, some caution appears
in order in using related donors, especially HLA-identical siblings,
when we transplant kidneys into patients with renal failure caused
by IgAN. On the other hand, keep in mind that only a minority of
patients with recurrent pIgAN progress to renal failure after
receiving a transplant.
DR. VAN Es: Let me tell you what we are doing. We are
performing a study in all transplant recipients who originally had
biopsy-proven IgA nephropathy. The risk of recurrence of IgA
deposits in the glomeruli is higher in patients who receive a kidney
from a related donor than in patients with an unrelated donor.
However, very few recipients have hematuria, and the GFR
remains stable in the large majority of patients. In view of the
excellent results that can be obtained in HLA-identical combina-
tions, I would proceed with the transplantation, when the donor is
genuinely motivated.
DR. COHEN: Dr. van Es, in those instances in which IgAN recurs
in the HLA-identical transplant, do we know whether the donor
has an increased incidence of urinary abnormalities after dona-
tion?
DR. VAN Es: We recalled all our individuals who donated
kidneys to IgA nephropathy patients since 1966 and found a 10%
prevalence of hypertension, not significantly different from the
control population. We did not find hematuria in these donors.
DR. MICHEL LE5KI (Division of Nephrology, Hôpital Cantonal
Universitaire, Geneva, Switzerland): Are you prescribing ACE
inhibitors for all patients with IgA nephropathy, even when they
are normotensive and do not have proteinuria?
DR. SCHENA: We normally prescribe ACE inhibitors in pIgAN
patients whose daily proteinuria exceeds 1 g. In our hands, ACE
inhibitors are not efficient when proteinuria is more than 3 glday.
We do not administer these drugs in pIgAN patients without
proteinuria, although some recent studies have shown that
ramipril, an ACE inhibitor of the latest generation, can reduce the
increase in DNA synthesis induced by fetal calf serum and PDGF
BB in cultured human mesangial cells (unpublished data). The
potential benefits of ACE inhibitors, administered in patients with
mild or moderate renal changes, might be inferred by the inhibi-
tion of angiotensin II formation. Indeed, ACE inhibitors reduce
the interstitial deposition of type-IV collagen in a model of
chronic ureteral obstruction in the rat [113].
DR. TILMAN DRUEKE (Professor, Department of Nephrology,
Hôpital Necker, Paris): I have a comment and a question. You said
that there was no relation between cytokine or growth factor
levels in the circulation and the severity of glomerular disease in
IgAN. I think that the recent paper by Lai et a! demonstrates a
correlation between TGF production by peripheral CD4 + T-
cells and the degree of glomerulosclerosis in IgA nephropathy
[94].
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You showed an increased IgA production by PBMC in relatives
of patients with IgA nephropathy who had no evidence of renal
abnormalities. The increase was present in more than 50% of
relatives. Would this observation favor an environmental factor
rather than a genetic factor?
DR. SCHENA: We demonstrated in vitro a moderate, spontane-
ous production of IgA by PBMC of apparently healthy relatives,
which increased significantly after PWM stimulation, regardless of
the occurrence of urinary abnormalities [53]. We did not check for
a Mendelian distribution of this abnormality; however, using
linkage analysis, a systematic study is being performed. Actually,
it is hard to envision how an environmental factor could be
responsible for this familial abnormality of the IgA system, unless
we accept an underlying predisposing genetic factor.
DR. KASSIRER: I do not believe that routine renal biopsies of
patients with persistent isolated hematuria are justified. Even
though the risk of biopsy is extremely small, there is little evidence
that the results will benefit the patient. Collecting data on
prevalence of various glomerulopathies is not, in my opinion, a
sufficient justification for such a study.
DR. SCHENA: Your comment reflects the renal biopsy policy of
many American nephrology units; for this reason, pIgAN appar-
ently is not as frequent in the USA as in Europe and Asia [21. In
the last 10 years, some American nephrologists have focused on
this disease. The more frequent use of renal biopsy by some
investigators in patients with persistent isolated microhematuria
or recurrent macrohematuria has shown a high incidence of IgAN
in the general US population (36%) and in southwestern Amer-
ican Indians (35%) [114, 1151. Moreover, I would like to point out
the importance of renal biopsy as a prognostic indicator.
DR. MADIAS: Do you recommend a liberal biopsy policy in the
context of research projects or as a matter of practice?
DR. SCHENA: I recommend performing renal biopsy in patients
with recurrent episodes of macrohematuria and in those with
persistent microhematuria and mild proteinuria (more than 1
glday) after the exclusion of urologic causes. More than 5000 red
blood cells/mm in the urine are a reliable indicator of disease.
Persistent microhematuria with red blood cell counts of more
than 105/ml likely indicates the presence of crescents affecting
glomeruli [1101. In our experience, this policy has revealed a large
number of patients with mild renal lesions, and a few with
moderate renal lesions, which progress to end-stage renal disease
in 50% of patients. Thus, I support the use of renal biopsy for
clinical purposes, as I indicated earlier. Moreover, the application
of molecular biology techniques to renal biopsies with moderate
changes should help collect further information on the role of
cytokines and growth factors.
DR. JORDAN J. COHEN (President, Association of American
Medical Colleges, Washington, DC): The finding that IgA nephrop-
athy recurs in transplanted kidneys more frequently in HLA-
identical donor-recipient pairs than otherwise would appear to
support the view that genetic factors are important. Is this
interpretation correct?
DR. SCHENA: Yes, your interpretation is correct. However, I
should emphasize that environmental factors such as infectious
agents and dietary habits can contribute to familial pIgAN even
though an epidemologic study performed by Julian et al in a
200-year-old pedigree encompassing seven generations did not
reveal a common environmental factor [441.
DR. YVES PIRSON (Associate Professor, University of Louvain
Medical School, Brussels, Belgium): I have two questions. In regard
to the outcome of renal transplantation in patients with IgA
nephropathy, patients with IgA nephropathy have better graft
tolerance than do those with other types of chronic glomerulone-
phritis [116], possibly because of a protective effect of IgA [117].
Would you comment on this point? Second, with respect to the
risk of recurrence of the disease after transplantation, are there
any risk factors for recurrence that are identifiable before trans-
plantation?
DR. SCHENA: In 1992 Lim and Terasaki showed that the graft
survival rate of patients receiving a first transplanted kidney from
a cadaveric donor was 76% at 5 years post transplant in 374 IgAN
patients, compared with 50% to 60% among patients with other
renal diseases who received transplants [116]. In a subsequent
study by the same group, Koka and coworkers demonstrated that
one-year graft survival of IgAN patients with IgA anti-HLA class-I
antibodies was far superior (91%) to that of those without the
antibody (58%) [1181. In contrast, IgG antibodies were deleteri-
ous; at one year, graft survival was 74% in patients with IgG
antibodies compared with 87% in those without antibodies [118].
This group concluded that IgA antibodies contribute to renal graft
survival by blocking IgG or 1gM antibodies against the trans-
planted organ, especially during the early post-transplant phase.
In fact, Lim et al, in an in-vitro study, showed that high pre-
transplant serum levels of IgA antibodies to HLA class-I antibod-
ies are able to block IgG anti-HLA antibodies [117].
Actually, other hypotheses have been advanced, such as the
non-complement immune fixation of the IgA. Still, this aspect is
controversial; some investigators demonstrated activation of the
complement system by IgA in an in-vivo rat model [119, 120].
However, I do not have an answer for your second question,
because risk factors have not yet been identified.
DR. MnIAs: I believe that IgA anti-mesangial cell autoantibod-
ies have been described in some patients with IgAN [121]. Have
you observed this in your cases, whether familial or non-familial?
DR. SCHENA: We studied the occurrence of another autoanti-
body, the IgA rheumatoid factor, in patients and their relatives
[53]. We found high serum levels of IgA rheumatoid factor in
pIgAN patients and in 25% of their relatives. The presence of the
IgA rheumatoid factor might indicate the reduced function of Ta
suppressor cells and the increased activity of Ta helper cells,
which have been demonstrated in patients with pIgAN.
DR. ALLEGRI: In what percentage of patients do IgA renal
deposits disappear during the course of the disease, thus simulat-
ing another type of nephropathy if biopsy is performed late?
DR. SCHENA: Serial renal biopsies performed in patients with
pIgAN have shown the persistence of mesangial IgA deposits,
even in those in whom urinalysis became normal. Usually patients
with biopsy-proven IgAN do not undergo a second renal biopsy
after entering clinical remission. In a few cases, however, immu-
nofluorescent study has not shown the persistence of IgA deposits.
Julian and collegues reviewed the literature on this topic [122].
They quoted six papers in which the disappearance of mesangial
IgA deposits was described in 10 rebiopsied patients. The disap-
pearance of IgA deposits might be due to many factors, such as
the rate of synthesis of IgA and of the clearance of IgA immune
complexes.
DR. LESAVRE: In the study of patients with recurrent IgA
nephropathy who had received transplants, I believe that immu-
nologic abnormalities help predict recurrence. In the 1980s, we
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demonstrated that serum conglutinin reactive IgA, negatively
charged IgA, and IgA rheumatoid factor were associated with the
recurrence of mesangial IgA deposits in transplanted kidneys. The
situation is clear-cut because serum from transplanted patients
with or without recurrence were studied blindly [123, 124]. When
we combined the three immunologic abnormalities, it appeared
that predictability of recurrence was almost total. However, this
probably had little clinical interest because relapse has no clinical
importance in that disease.
DR. ARTURO BORSATFI (Professor of Nephrology, University of
Padova, Padova, Italy): Do you believe it is possible to identify an
acute phase of IgA nephropathy?
DR. SCHENA: Many nephrologists define the acute phase of
pIgAN as the occurrence of fever, infections of the upper
respiratory tract, and macrohematuria. In this phase, relapsed
patients show an increased number of IgG and IgA secretory cells
[99] and high serum levels of circulating IgAl-IgG immune
complexes [58]. We observed in vitro an increased spontaneous
production of IL-2 by PBMC during the acute phase of the
disease, which reversed completely during followup; the same
behavior was observed with PHA-stimulated PBMC [731 These
findings demonstrate that the "hyperactive" IgA system of pa-
tients with pIgAN is further stimulated during the active phase of
the disease, when there is also the participation of the IgG system,
which is presumably responsible for the activation of the comple-
ment system.
DR. SAND0R S0NK0DI (Head, Nephrology Section, Albert Szent-
Gyorgyi Medical University, Szeged, Hungary): I would like to ask a
question in connection with the link between IgA nephropathy
and tonsillitis. You referred to data indicating an increase in the
number of IgAl-producing plasma cells in tonsils of patients with
IgAN compared with controls. Do you think that tonsillitis is an
important factor in the development of the disease? In your
experience, is tonsillectomy beneficial?
DR. SCHENA: Actually Bené et al [125] and Egido and col-
leagues [126] showed an inverted IgG/IgA ratio in the tonsils of
patients with pIgAN and hypothesized that this abnormality was
due to an increased amount of IgA-producing plasma cells in
palatine tonsils or to an abnormal switch mechanism favoring the
IgA. In a clinical and immunologic followup study of biologic
parameters performed in 34 tonsillectomized patients with IgA
nephropathy, Bené and coworkers demonstrated a decrease in
serum IgA levels and proteinuria 6 months after tonsillectomy;
however, no variation of serum creatinine values was observed
[127]. Others recently have claimed that tonsillectomy is a valid
therapeutic measure in patients with frequent tonsillitis because it
reduces the rate of deterioration of renal function [128]. However,
we cannot exclude that other infections, such as pharyngitis and
bronchitis in tonsillectomized patients, influence the renal dis-
ease.
DR. V0sNIDEs: You mentioned the presence of IgA-rheumatoid
factor in the serum of patients with IgA nephropathy. How
common is this finding?
DR. SCHENA: IgA rheumatoid factor has been found in 41% of
patients with pIgAN [129]. Autoantibodies against laminin,
ssDNA, endothelial cells, and lymphocytes have been observed in
a few cases, and rarely anti-neutrophil cytoplasmic antibodies and
anti-GBM IgA class antibodies have been found.
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